Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company's pipeline contains lead candidate BDC-1001, a HER2 Boltbody Immune-Stimulating Antibody Conjugate. In preclinical safety studies, BDC-1001 was well tolerated and no adverse safety signals were observed. BDC-1001 is currently in a Phase 1/2 trial for the treatment of patients with HER2-expressing solid tumors, and the company expects to move into Phase 2 dose expansions in key solid tumor indications with unmet medical need in 2021.
The Redwood City, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol BOLT. Bolt Biotherapeutics filed confidentially on August 10, 2020. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
